Silverman L B, Weinstein H J
Harvard Medical School, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02215, USA.
Curr Opin Oncol. 1997 Jan;9(1):26-33. doi: 10.1097/00001622-199701000-00005.
The development of successful therapy for most children with acute lymphoblastic leukemia can be attributed to sequential clinical studies that show the importance of combination chemotherapy, sanctuary-specific treatment, and supportive care measures. The relative resistance of acute myelogenous leukemia to chemotherapy led to strategies that include dose-intensified chemotherapy and bone marrow transplantation. The improvement in long-term survival for children with acute leukemia has been gratifying but also has been associated with late effects that underscore the need for careful follow-up and for designing risk-adapted therapies.
大多数急性淋巴细胞白血病患儿成功治疗方法的发展可归功于一系列临床研究，这些研究表明了联合化疗、针对庇护所部位的治疗以及支持性护理措施的重要性。急性髓性白血病对化疗的相对耐药性促使人们采取了包括强化剂量化疗和骨髓移植在内的策略。急性白血病患儿长期生存率的提高令人欣慰，但也伴随着一些晚期效应，这突出了仔细随访和设计风险适应性治疗方法的必要性。
